New recommendations prioritise multiparametric MRI, safer transperineal biopsy, and earlier escalation for high-risk prostate ...
Fluorine-18 prostate-specific membrane antigen (PSMA)-1007 PET/CT was superior to multiparametric MRI for primary locoregional staging of prostate cancer, according to results from a phase II ...
Comprehensive genomic profiling of solid tumors from 677 adolescents and young adults for revealing a distinct spectrum of targetable genomic alterations. Exploratory biomarker analysis of a phase I ...
The goal of this investigation from Germany was to prospectively compare multiparametric MRI (1H-MR spectroscopy (MRS), diffusion-weighted imaging (DWI), contrast-enhanced) and standard T2W MRI at 1.5 ...
A combined PSMA-PET/MRI scanner better detected clinically significant prostate cancer in men on active surveillance. The addition of piflufolastat F18 (18 F-DCFPyL) prostate-specific membrane antigen ...
Survival impact of initial local therapy selection for men under 60 with high risk prostate cancer. Prostate cancer (PCa) in 696 hypogonadal men with and without long-term testosterone therapy (TTh): ...
Please provide your email address to receive an email when new articles are posted on . Use of multiparametric MRI led to significantly higher diagnosis rates in all hospitals studied. Patients ...
Results from the phase 3 PRECISE trial showed that MRI with targeted biopsies matched or exceeded the accuracy of the current standard for detecting clinically significant prostate cancer. The current ...
Prostate MRI currently lacks the accuracy to replace biopsies in active surveillance for prostate cancer. The negative predictive value of MRI remains below 90%, the general goal for safely avoiding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback